SAN FRANCISCO -- Janus kinase (JAK) inhibitors appeared to be a safe, effective option for treating inflammatory bowel disease (IBD) in older adults, according to two poster presentations.
A study from the FIRST registry finds that rheumatoid arthritis patients with an inadequate response to JAK inhibitors may ...
For rheumatoid arthritis patients with inadequate response to JAK inhibitors, new research suggests cycling to another JAKi ...
The Janus kinase inhibitor baricitinib ... demonstrated the ability to reduce the disease activity score compared to placebo, suggesting that baricitinib effectively halted disease progression ...
No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback